William K. Oh, MD

William K. Oh, MD

Icahn School of Medicine at Mount Sinai

New York, New York

Dr. William K. Oh is Chief Medical Officer at the Prostate Cancer Foundation (PCF), the world’s leading philanthropic organization dedicated to the eradication of prostate cancer and is also a Clinical Professor of Medicine in the Division of Hematology and Medical Oncology at The Tisch Cancer Institute of the Icahn School of Medicine at Mount Sinai. He is an expert in the management of genitourinary malignancies, including prostate, renal, bladder, and testicular cancers. Dr. Oh received his MD from New York University School of Medicine. He completed his internship and residency in internal medicine at Brigham and Women’s Hospital in Boston. Dr. Oh completed a fellowship in medical oncology at the Dana-Farber Cancer Institute. For two years prior to joining PCF, Dr. Oh was the Chief Medical Officer at Sema4, a patient-centered health intelligence company. From 2009-2020, Dr. Oh was Chief of the Division of Hematology and Medical Oncology at the Mount Sinai Health System and Deputy Director of The Tisch Cancer Institute, an NCI-designated cancer center, at Mount Sinai. Dr. Oh spent 14 years at Harvard Medical School and the Dana-Farber Cancer Institute in Boston, including service as Clinical Director of GU Oncology and Associate Professor of Medicine. Dr. Oh has authored more than 350 original articles, reviews, and book chapters on topics relating to prostate, renal, bladder, and testicular cancers. He has edited three books on prostate cancer. He has served in key invited roles for the American Society of Clinical Oncology (ASCO), the American Cancer Society (ACS), and the American Urological Association (AUA), including the Guidelines Committee for Castration-Resistant Prostate Cancer. In addition to reviewing for prominent journals such as the New England Journal of Medicine, Journal of Clinical Oncology, and Cancer, Dr. Oh was inducted into the prestigious American Society for Clinical Investigation (ASCI) and has been repeatedly selected as a Top Doctor in New York Magazine, Castle Connolly, Best Doctors, and Super Doctors.

Disclosures:

Talks by William K. Oh, MD

New Standards of Care for Advanced Prostate Cancer

In this 20-minute presentation, William K. Oh, MD, Chief of the Division of Hematology and Medical Oncology at the Mount Sinai Health System and Deputy Director of The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, addresses new standards of care in 2021 for advanced prostate cancer and focuses on non-metastatic castration-resistant prostate cancer (nmCRPC), concluding that apalutamide, enzalutamide, and darolutamide improve MFS in men with nmCRPC by ~2 years; SPARTAN, PROSPER, and ARAMIS established favorable benefit-risk for patients with nmCRPC and PSADT<10 months; and these studies provide the best evidence supporting early treatment. He also focuses on metastatic, hormone-sensitive prostate cancer (mHSPC) and concludes that upfront treatment with either abiraterone + prednisone, apalutamide, enzalutamide, or docetaxel is the standard of care and he asserts that new evidence from PEACE-1 and ARASENS supports triple therapy with a novel hormonal therapy +ADT+docetaxel for chemotherapy patients.

Read More

Join the GRU Community

- Why Join? -